Sunovion Pharmaceuticals Inc.

Pgi Drug Discovery LLC

Carrie A Bowen

Linghong Xie

Michele L R Heffernan

Douglas F Burdi

Lee W Herman

Seth C Hopkins

Scott C Malcolm

Taleen G Hanania

Noel Aaron Powell

Vadim Alexandrov

Laurence Melnick

Colleen M Synan

Scott Malcolm

The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

Methods of treating neurological and psychiatric disorders

Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.

Heteroaryl-isochroman compounds and uses thereof

Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need thereof are also disclosed.

Compounds and compositions and uses thereof

Compounds and uses thereof

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as pain, neurological disorders, psychiatric disorders, and neuromuscular disorders. Compounds provided herein modulate the activity of opioid receptor (e.g., &#x3bc;-opioid receptor) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Modulators of opioid receptors and methods of use thereof

Growing community of inventors

Uxbridge, MA, United States of America

Carrie A Bowen